2025 Dealmakers of the Year Honorees
Presented By: HUB International
Matthew Berry
Founder
Fantasy Life
Sr. Fantasy Sports & Sports Betting Analyst
NBC Sports
Fantasy Life, the leading fantasy sports and sports betting media company founded by Matthew Berry, acquired Guillotine Leagues, the fast-growing fantasy gaming platform that offers a new take on fantasy football. The addition of Guillotine Leagues provides another top-tier fantasy offering to the sports community. The highly addictive game features weekly eliminations, star players on waivers, leagues starting every week throughout the season and unprecedented excitement to all fans.
Joon Chang
Co-Founder
Vijay Mehta
Co-Founder
Arkview Capital
Arkview Parking, with operating partner, Icon Parking formed an innovative Joint Venture with Tishman Speyer in January 2025. Despite the changing political landscape, Arkview & Tishman Speyer has remained steadfast in its commitment to reflect the diverse communities it serves across the country. The contract is worth over $80M in Tier 1 Diversity Spend over three years. This unique Joint Venture helps to provide high-quality, essential parking services for a world-class real estate development firm, while contributing to the bottom line of both organizations and the communities it serves. This deal is the largest in Arkview Parking and Icon Parking’s history, taking a long-standing New York brand to the national level, with operations in Seattle, San Francisco, Los Angeles, Chicago, and New York City. The Joint Venture allows Tishman Speyer to get closer to its goal of reaching the Billion Dollar Roundtable, reserved for organizations that spend $1B+ dollars with MWBE certified suppliers.
Brandon Richter
Partner
Hamilton Robinson Capital Partners
James Parmelee
Managing Director
Hamilton Robinson Capital Partners
James Gillespie
CEO
GrayMatter
GrayMatter is an industrial intelligence company that helps clients architect and implement operational technologies in their manufacturing operations. The company was founded in 1991 by entrepreneurs Jim Gillespie and Carson Drake. In 2017, GrayMatter management partnered with Hamilton Robinson Capital Partners to drive the next phase of growth in the business. Over the next six years, GrayMatter invested heavily in its engineering and delivery team, expanded geographically and broadened its portfolio of solutions both organically and through five strategic acquisitions. The company nearly quadrupled in revenue during the hold period while diversifying its customers, end markets and vendor partners. Along the way, 84 GrayMatter managers and employees, who were so instrumental in achieving this success, became shareholders of the company alongside Hamilton Robinson. After building a foundation and proven platform for value creation, Tailwind Capital recapitalized the business in 2024 with the management shareholders reinvesting for the next phase of growth.
Edwin Tan
Managing Partner
Robert Tucker
Managing Partner
Andrea Nelson
Principal
John Newman
Managing Director
Heartwood Partners IV, LP
Heartwood Partners completed an investment in Bush Brothers in July of 2023. Bush Brothers, a fifth-generation family-run business, is a value-added distributor of premium meat products selling into restaurants, hotels, country clubs, yachts, and other high-end markets in Florida and the Caribbean. In partnership with the Bush family, Heartwood provided investment to accelerate organic growth plans, including for a brand new state-of-the-art facility, while supporting their commitment to unrelenting service for customers and the preservation of their family business culture.
Gary Zammit
President & CEO
Eileen M. McAuley
Chief Operating Officer
Clinilabs Drug Development Corporation
InTandem Capital Partners, a healthcare services-focused private equity rm, partnered with the founder and management team at Clinilabs, a global, full-service contract research organization dedicated to providing a complete range of central nervous system drug and device development services to the pharmaceutical, biotechnology, and medical technology industries. Since the Company’s inception in 2000, Clinilabs has established itself as a market leader in neuroscience therapeutics, focusing eorts exclusively in neurology, psychiatry, addiction, and rare CNS disorders.